Calculators and Tools for Atrial Fibrillation

AHA/ACC 2023 guidelines recommend oral anticoagulation for non-valvular AFib with CHA₂DS₂-VASc ≥2 (men) or ≥3 (women). Score 1 (men) or 2 (women): anticoagulation is reasonable — shared decision-making based on patient preference and bleeding risk. Score 0 (men) or 1 (women): anticoagulation not recommended. DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for non-valvular AFib due to superior efficacy, safety, and convenience. Warfarin remains first-line for mechanical heart valves and rheumatic mitral stenosis.

HAS-BLED estimates annual major bleeding risk: Hypertension (uncontrolled), Abnormal renal/liver function, Stroke history, Bleeding history/predisposition, Labile INR (on warfarin), Elderly (age >65), Drugs (antiplatelets/NSAIDs) or alcohol. Score 0–1 = low risk; 2 = intermediate; ≥3 = high risk. Importantly, a high HAS-BLED score should not automatically withhold anticoagulation — it should prompt identification and correction of modifiable bleeding risk factors (control BP, review antiplatelet use, minimize NSAIDs, reduce alcohol). The net clinical benefit of anticoagulation typically outweighs bleeding risk even at HAS-BLED ≥3.

Class IC agents (flecainide, propafenone) are contraindicated in structural heart disease — not primarily a QTc concern but monitor for intraventricular conduction prolongation. Class III agents (amiodarone, sotalol, dofetilide, dronedarone) prolong QTc — obtain baseline ECG and monitor during initiation. Dofetilide requires in-hospital initiation with continuous QTc monitoring (risk of torsades de pointes). Sotalol should not be started if QTc >450–500 ms. Amiodarone has the lowest torsades risk despite significant QTc prolongation. Target QTc <500 ms for all antiarrhythmics.

Rate control (target resting HR <80 bpm per RACE II) uses beta-blockers, diltiazem/verapamil, or digoxin. Rhythm control (restoring sinus rhythm) uses cardioversion, antiarrhythmic drugs, or catheter ablation. The AFFIRM and RACE trials showed no mortality difference between strategies for most patients. However, the EAST-AFNET 4 trial (2020) showed early rhythm control in newly diagnosed AFib significantly reduced cardiovascular death, stroke, and HF hospitalization. Current guidelines favor early rhythm control, especially in younger patients, those with significant symptoms, or HFrEF (where AFib ablation improves mortality — CASTLE-AF).

All DOACs require dose adjustment in CKD. Key thresholds: Apixaban 2.5 mg BID dose reduction (if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL); Rivaroxaban 15 mg daily at CrCl 15–50 (avoid <15); Dabigatran reduce at CrCl 30–50, avoid at <30 (or use CrCl <15); Edoxaban 30 mg at CrCl 15–50. At eGFR <15 or dialysis, warfarin is traditionally used — though evidence for DOACs is emerging in ESKD. Use Cockcroft-Gault (not CKD-EPI) for DOAC dosing decisions.

Patients with AFib have a 2-fold increased risk of MI independent of shared risk factors. Aggressive cardiovascular risk factor management is essential: blood pressure <130/80 mmHg, statin therapy for ASCVD risk ≥7.5% (or established CVD), diabetes management (HbA1c <7%), and obesity treatment. The Framingham Risk Score and ASCVD Pooled Cohort Equations apply in AFib. Notably, anticoagulation for AFib does not prevent MI — antiplatelet therapy is added only for acute coronary syndromes (and discontinued as soon as safely possible to minimize bleeding when combined with anticoagulation).